Dr. Reddy's Laboratories Dividends and Buybacks
Dividend criteria checks 0/6
Dr. Reddy's Laboratories is a dividend paying company with a current yield of 0.58%.
Key information
0.6%
Dividend yield
-0.02%
Buyback Yield
| Total Shareholder Yield | 0.6% |
| Future Dividend Yield | 0.7% |
| Dividend Growth | -1.0% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | US$0.0958 |
| Payout ratio | 12% |
Recent dividend and buyback updates
Recent updates
Dr. Reddy's Laboratories: Economic Factors Square Off To Reiterate Buy
Aug 13Dr. Reddy's Laboratories: Q2 Earnings Reveals Strong Growth And Promising Advancements
Nov 29Dr. Reddy's: Continued Q2 Earnings Growth, Supports Long-Term Investment Outlook
Oct 27Dr. Reddy's: Growth Supported By New Labels, Profitability
Aug 23Dr. Reddy's Laboratories: Unpacking The Critical Factors, Reiterate Buy
Jun 07Dr. Reddy's Laboratories: Positive Q3 Results, Growth Supportive Of Buy
Feb 16Dr. Reddy's prepare to file for Rituxan biosimilar in US, EU as trials completed
Jan 20Dr. Reddy's Needs Time For Generics Sales To Replace Sputnik Revenue
Nov 07Dr. Reddy's GAAP EPS of $0.90, revenue of $660M misses by $12.78M
Jul 28Dr. Reddy's launches generic drugs for allergies in US
Jul 22Dr. Reddy's, EQRx team up to develop drugs for cancer, immune-inflammatory diseases
Jul 05Stability and Growth of Payments
Fetching dividends data
Stable Dividend: RDY is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: RDY is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Dividend Yield vs Market
| Dr. Reddy's Laboratories Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (RDY) | 0.6% |
| Market Bottom 25% (US) | 1.5% |
| Market Top 25% (US) | 4.6% |
| Industry Average (Pharmaceuticals) | 2.5% |
| Analyst forecast (RDY) (up to 3 years) | 0.7% |
Notable Dividend: RDY's dividend (0.58%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.47%).
High Dividend: RDY's dividend (0.58%) is low compared to the top 25% of dividend payers in the US market (4.57%).
Earnings Payout to Shareholders
Earnings Coverage: RDY is not paying a notable dividend for the US market.
Cash Payout to Shareholders
Cash Flow Coverage: RDY is not paying a notable dividend for the US market.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 12:35 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dr. Reddy's Laboratories Limited is covered by 81 analysts. 36 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nitin Bhasin | Ambit Capital |
| Prashant Nair | Ambit Capital |
| null null | Anand Rathi Shares and Stock Brokers Limited |